Literature DB >> 396336

Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection.

K R Beutner, T Chow, E Rubi, J Strussenberg, J Clement, P L Ogra.   

Abstract

Three groups of children were immunized with an inactivated Port Chalmers (H3ChN2Ch) influenza vaccine (group A), a neuraminidase-specific (Heq1N2Ch) influenza vaccine (group B), or a placebo. Immunization induced seroconversion for H3Ch and N2Ch-specific antibody in group A and for N2Ch antibody in group B. The protective efficacies observed against naturally acquired illness with the Port Chalmers strain of influneza A virus were 68.7% and 37.4% in groups A and B, respectively, in comparison to the placebo group, and those against illness produced by the subsequent outbreak of the Victoria strain were 80.0% and 72.7%. These data support the role of neuraminidase-specific immunization in protection against influenza. Although the degree of protection after vaccination with the Heq1N2Ch vaccine was less than that provided by the biphasic H3ChN2Ch vaccine against the Port Chalmers strain, it appeared to be similar in the two vaccine study groups against the Victoria strain.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 396336     DOI: 10.1093/infdis/140.6.844

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.

Authors:  Bolyn Hubby; Todd Talarico; Maureen Maughan; Elizabeth A Reap; Peter Berglund; Kurt I Kamrud; Laura Copp; Whitney Lewis; Chad Cecil; Pamela Norberg; Jordan Wagner; Aubrey Watson; Sarah Negri; Bruce K Burnett; Andrew Graham; Jonathan F Smith; Jeffrey D Chulay
Journal:  Vaccine       Date:  2007-10-05       Impact factor: 3.641

Review 2.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

Review 3.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

4.  Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.

Authors:  Gale E Smith; Xiangjie Sun; Yaohui Bai; Ye V Liu; Michael J Massare; Melissa B Pearce; Jessica A Belser; Taronna R Maines; Hannah M Creager; Gregory M Glenn; David Flyer; Peter Pushko; Min Z Levine; Terrence M Tumpey
Journal:  Virology       Date:  2017-06-16       Impact factor: 3.616

5.  Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus.

Authors:  M L Clements; R F Betts; E L Tierney; B R Murphy
Journal:  J Clin Microbiol       Date:  1986-07       Impact factor: 5.948

6.  Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection.

Authors:  B E Johansson; D J Bucher; E D Kilbourne
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

7.  Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations.

Authors:  A P Kendal; F M Bozeman; F A Ennis
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

Review 8.  Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks.

Authors:  Joel V Chua; Wilbur H Chen
Journal:  Crit Care       Date:  2010-04-16       Impact factor: 9.097

9.  Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection.

Authors:  Hongquan Wan; Li Qi; Jin Gao; Laura K Couzens; Lianlian Jiang; Yamei Gao; Zong-Mei Sheng; Sharon Fong; Megan Hahn; Surender Khurana; Jeffery K Taubenberger; Maryna C Eichelberger
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

Review 10.  New approaches to influenza chemotherapy. Neuraminidase inhibitors.

Authors:  D P Calfee; F G Hayden
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.